141
Views
6
CrossRef citations to date
0
Altmetric
Drug Evaluation

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

&
Pages 617-621 | Published online: 23 Mar 2006

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Bala Waziri, Raquel Duarte & Saraladevi Naicker. (2019) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Current Perspectives. International Journal of Nephrology and Renovascular Disease 12, pages 263-276.
Read now
Halil Zeki Tonbul, Yalcin Solak, Huseyin Atalay, Kultigin Turkmen & Lutfullah Altintepe. (2012) Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study. Renal Failure 34:3, pages 297-303.
Read now

Articles from other publishers (4)

Pablo Antonio Ureña-Torres, Mario Cozzolino & Jordi Bover. (2018) Utilisation de l’alfacalcidol et des analogues actifs de la vitamine D dans la maladie rénale chronique. Néphrologie & Thérapeutique 14:4, pages 189-200.
Crossref
TONG ZHU, TIAN-JING LIU, YONG-YAN SHI & QUN ZHAO. (2015) Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. International Journal of Molecular Medicine 35:5, pages 1213-1218.
Crossref
J. Ruth Wu-Wong, Masaki Nakane & Yung-wu Chen. (2013) Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. Life Sciences 92:2, pages 161-166.
Crossref
Neal Mittman, Brinda Desiraju, Kevin B. Meyer, Jyoti Chattopadhyay & Morrell M. Avram. (2010) Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney International 78, pages S33-S36.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.